Blinatumomab for B-cell precursor ALL: From hospital to home
24 Oct 2025
byDr. Carol Cheung, Specialist in Haematology & Haematological Oncology; Ms. Kitty Leung, Clinical pharmacist
Blinatumomab, a bispecific T cell–engager antibody administered as a continuous intravenous (IV) infusion, has several indications in B-cell precursor acute lymphoblastic leukaemia (ALL). Traditionally, in Hong Kong, patients receiving blinatumomab are hospitalized for 28-day treatment cycles. In an interview with MIMS Oncology, Dr Carol Cheung, Specialist in Haematology & Haematological Oncology, and clinical pharmacist Ms Kitty Leung shared insights into how a proactive outpatient infusion protocol at a local hospital has enabled patients to receive blinatumomab at home. They discussed how home infusion of blinatumomab works, along with its risks, challenges, and benefits for both patients and healthcare providers.
